title: Safety and five-year re-intervention following magnetic resonance-guided focused ultrasound (MRgFUS) for uterine fibroids.
abstract: OBJECTIVE
  To examine the safety and re-intervention rates following magnetic resonance-guided focused ultrasound (MRgFUS) for uterine fibroids at 5 years. To assess how the non-perfused volume (NPV), fibroid signal intensity and use of gonadotrophin-releasing hormone analogues (GnRHa) affect the re-intervention rates.
  
  
  METHODS
  Cohort study of women undergoing MRgFUS for treatment of their uterine fibroids between 2003 and 2010.
  
  
  RESULTS
  Of 280 women undergoing MRgFUS the rate of minor complications was 3.9% and there were 3 serious complications (1.1%) including one skin burn, a fibroid expulsion and one case of persistent neuropathy. The NPVs achieved following MRgFUS have increased as the experience with this treatment has grown. In a 5-year follow-up study of 162 women, the overall re-intervention rate was 58.64%, but in those treatments with greater than 50% NPV the re-intervention rate was 50%.
  
  
  CONCLUSIONS
  MRgFUS treatment of uterine fibroids is a safe treatment for uterine fibroids. The re-intervention rate at 5 years is high, but the improvements in NPVs achieved may further improve the long term results.
authors.affiliation: Department of Obstetrics and Gynaecology, St. Mary's Hospital, Praed Street, London W2 1NY, United Kingdom. Electronic address: Stephen.quinn@imperial.nhs.uk.
authors.forename: S D
authors.initials: SD
authors.lastname: Quinn
authors.affiliation: Department of Radiology, St. Mary's Hospital, Praed Street, London W2 1NY, United Kingdom. Electronic address: John_vedelago@yahoo.com.
authors.forename: J
authors.initials: J
authors.lastname: Vedelago
authors.affiliation: Department of Radiology, St. Mary's Hospital, Praed Street, London W2 1NY, United Kingdom. Electronic address: w.gedroyc@imperial.ac.uk.
authors.forename: W
authors.initials: W
authors.lastname: Gedroyc
authors.affiliation: Department of Obstetrics and Gynaecology, St. Mary's Hospital, Praed Street, London W2 1NY, United Kingdom. Electronic address: l.regan@imperial.ac.uk.
authors.forename: L
authors.initials: L
authors.lastname: Regan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D057086:High-Intensity Focused Ultrasound Ablation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007889:Leiomyoma / Q000473:pathology / Q000601:surgery*; D053783:Magnetic Resonance Imaging, Interventional; D008875:Middle Aged; D012086:Reoperation; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden; D014594:Uterine Neoplasms / Q000473:pathology / Q000601:surgery*
chemical_list: D007987:Gonadotropin-Releasing Hormone
keywords: Fibroids; Magnetic resonance-guided focused ultrasound (MRgFUS); Treatment’ follow-up